[go: up one dir, main page]

PE20091464A1 - Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas - Google Patents

Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas

Info

Publication number
PE20091464A1
PE20091464A1 PE2009000255A PE2009000255A PE20091464A1 PE 20091464 A1 PE20091464 A1 PE 20091464A1 PE 2009000255 A PE2009000255 A PE 2009000255A PE 2009000255 A PE2009000255 A PE 2009000255A PE 20091464 A1 PE20091464 A1 PE 20091464A1
Authority
PE
Peru
Prior art keywords
pelets
compound
pharmulation
oxabispidins
modified release
Prior art date
Application number
PE2009000255A
Other languages
English (en)
Inventor
Anders R Berggren
Hans Carlsson
Hans Jonsson
Kristina Roos
Erik Soderlind
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091464A1 publication Critical patent/PE20091464A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA DE LIBERACION MODIFICADA EN FORMA DE SISTEMA DE UNIDADES MULTIPLES TAL COMO CAPSULAS, TABLETAS O SACHETS, QUE COMPRENDE: i) PELETS DE LIBERACION INMEDIATA QUE COMPRENDEN UN COMPUESTO DE OXABISPIDINA TAL COMO (2-{7-[2-(4-CIANO-2-FLUOROFENOXI)ETIL]-9-OXA-3,7-DIAZABICICLO-[3.3.1]NON-3-IL}ETIL)CARBAMATO DE TERC-BUTILO (COMPUESTO A) Y ii) PELETS DE LIBERACION MODIFICADA QUE COMPRENDEN EL COMPUESTO A, RECUBIERTOS CON UNA MEMBRANA DE DIFUSION FORMADA POR UN POLIMERO FORMADOR DE PELICULA TAL COMO ETILCELULOSA O HIDROXIPROPILCELULOSA, DONDE LA RELACION ENTRE LOS PELETS DE TIPO i) Y ii) SE ENCUENTRA ENTRE 10:90 Y 90:10. DIHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS
PE2009000255A 2008-02-22 2009-02-20 Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas PE20091464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
PE20091464A1 true PE20091464A1 (es) 2009-10-24

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000255A PE20091464A1 (es) 2008-02-22 2009-02-20 Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas

Country Status (5)

Country Link
AR (1) AR070617A1 (es)
PE (1) PE20091464A1 (es)
TW (1) TW200940110A (es)
UY (1) UY31669A1 (es)
WO (1) WO2009105023A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (zh) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 一种埃索美拉唑镁微丸肠溶片及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7928225B2 (en) * 2005-06-13 2011-04-19 Astrazeneca Ab Oxabispidine compounds for the treatment of cardiac arrhythmias
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs

Also Published As

Publication number Publication date
TW200940110A (en) 2009-10-01
AR070617A1 (es) 2010-04-21
WO2009105023A1 (en) 2009-08-27
UY31669A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY30783A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos
UY30759A1 (es) Compuestos quimicos
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
EP2246052A4 (en) RASCH IN THE MOUTH DAMAGING TABLET WITH IMIDAFENACIN
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
CR10270A (es) Medicamentos que contienen fluoroquinolonas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
BRPI0917502A2 (pt) composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral
CO6351722A2 (es) Derivados heterociclicos de la urea y sus metodos de empleo
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2012003011A1 (es) Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.
EP2865664A4 (en) Novel compound having the ability to inhibit the enzyme 11B-HSD1 or its non-essential salt thereof, method of preparation thereof and pharmaceutical composition therewith as an active ingredient
CO6382113A2 (es) Compuestos quimicos
CO6771403A2 (es) Derivado de acilbenceno
EP2053038A4 (en) AMINO ALCOHOL DERIVATIVE AND THESE IMMUNOSUP PRESSIVES CONTAINING ACTIVE INGREDIENTS
PE20091464A1 (es) Formulacion farmaceutica de liberacion modificada que comprende oxabispidinas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal